Decoding the future of

transformative medicines

Our efforts are endless to unlock a world of life-changing
transformative medicines by utilizing Artificial Intelligence

About Us

BioXcel LLC utilizes advanced technologies such as AI (Artificial Intelligence) to develop transformative medicines at unprecedented speed in multiple therapeutic areas with high unmet needs. We are driven by scientific curiosity and passion for technology and embrace innovative approaches that help patients. We are optimizing research and development for productivity and creating novel and transformative medicines (or drugs).

Our AI-enabled platform, EvolverAI helps reduce development costs and accelerates the drug development timelines for a technologically-enabled, fast and efficient drug discovery process.

With the combination of our in-house human expertise and technological advancement, we can change the paradigm of drug discovery.

Our Family of Companies

BioXcel Therapeutics, Inc. is a biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing AI, and its approaches.

Learn More

InveniAI® LLC is a global leader in applying AI and ML tools to transform innovation across drug discovery and development by identifying and accelerating transformative therapies for diseases with unmet medical needs.

Learn More

A leading centre of research and innovation focused on developing transformative treatments. It integrates a rich and diverse cross-functional mix of highly qualified scientific, medical, commercial, IP, and Artificial Intelligence.

Learn More

Key Therapeutic AREAS

At every step of our journey, we make the most of our in-house scientific expertise. We believe with advanced technologies and well-researched endeavours, together we can create novel discoveries. BioXcel is deeply involved in creating breakthroughs in the following categories of diseases:


Excellence starts at the top. Meet our leaders who inspire us at every step of our journey


There is nothing more important than making people live healthier and longer lives. Check how BioXcel’s AI platform is extending the gift of science to people.

By utilizing this powerful AI platform EvolverAI, BioXcel Therapeutics successfully developed the first candidate medicine, IGALMI™ (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Our company performed this task in a matter of four years. We ensured that this medicine reached the patients and addressed a significant unmet need among patients and caregivers.

Our platform is decoding many therapeutic possibilities of a drug compound by the unique combination of subject matter experts and AI platform. We are hopeful that with the help of our AI platform, we are only steps away from incredible innovations that will not only cut short the time, but also the costs and risks associated with drug development. This will eventually lead to expanding the pipeline of potentially life-saving drug discoveries.

Strategy for Accelerating
Development Cycle through AI

With the right combination of human expertise, technology, and science, we can bring positive outcomes in patients’ lives by:

A Real Time Cloud Based Pharma Analytics Platform

A live and dynamic cloud-based pharma analytics platform revolutionizing decision making by providing live intelligence on treatment paradigms, product opportunities, key market movers, product blueprints, portfolio impact and commercial launch scenarios.

The suite's cognitive insights help identify potential market winners and streamline internal and external innovation, enabling better R&D prioritization and justifying sound investment decisions. Powered by an intuitive and interactive user interface that enables first mover advantage, predictive simulation, risk mitigation and operational excellence.

  • Drug Profiles
  • Treatment Paradigm
  • Disease Pathogenesis
  • Asset Assessment (Discovery, Preclinical, Clinical, Marketed)
  • Unmet Need
  • Performance Benchmarking
  • Portfolio Strategy
  • Licensing
  • Partnering Strategy
  • Business Development and Licensing

Our FDA approved IGALMI™ (dexmedetomidine) is now available.

Discover more


April 2022

BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics...

BioXcel Featured in Fierce Biotech The recent uptick in interest in drug repurposing, the popularity of which ebbs and flows, could give the team a tailwind..

April 2022

BioXcel Therapeutics Announces FDA Approval of IGALMI™...

First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia...

Dec 2021

InveniAI and Kyowa Kirin Expand AI-Driven Partnership..

- Collaboration enables Kyowa Kirin's R&D team to access InveniAI's data-driven discovery platform in expanded therapeutic areas...

July 2021

Sosei Heptares and InveniAI Enter a Multi-Target..

Collaboration to create transformative therapeutics for immune diseases by combining InveniAI's validated AI-based platform, AlphaMeld®,...

March 2016

Centrexion Therapeutics Expands Pain Pipeline with Acquisition of..

Much Needed Non-Opioid, Non-Addictive Pain Treatments are the Focus for Pain Therapeutics Development Efforts...

April 2015

Takeda, BioXcel Partner to Repurpose Compounds for Rare Diseases

BioXcel said today it has joined with Takeda Pharmaceutical’s U.S.-based global development group to repurpose...


Want to join us ?

Email at
+1 475 237 9007

Contact US

Email at
+1 475 237 9007